News
Reviva to Participate in the Lytham Partners Fall 2026 Investor Conference
The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend the corporate presentation at https://lythampartners.com/fall2026/ CUPERTINO, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE)...
Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights
- U.S. composition of matter patent application filed seeking accelerated review for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 - - FDA feedback on use of new brilaroxazine formulation in the RECOVER-2 trial and...
Reviva to Participate in Fireside Chat at A.G.P.’s Annual Healthcare Company Showcase
CUPERTINO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (OTCQB: RVPH) ("Reviva," the "Company" "we" or "us"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central...
Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights
- Composition of matter provisional patent application filed for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 - - FDA feedback on use of new form of brilaroxazine in the RECOVER-2 trial and future NDA expected in...
Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine’s Potential Across Multiple Neuropsychiatric Indications
CUPERTINO, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva," the "Company" "we" or "us"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central...
Reviva Announces Letter to Shareholders
CUPERTINO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva," the "Company" "we" or "us"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central...
Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights
- Written FDA recommendations include a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for schizophrenia - - Current data package highlights well-tolerated long-term safety profile, broad-spectrum clinical...
Reviva Pharmaceuticals Holdings, Inc. Announces Closing of $10 Million Public Offering
CUPERTINO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous...
Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering
CUPERTINO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous...
Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering
CUPERTINO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous...